Related Experiment Video
Updated: Feb 3, 2026

Direct Measurement of KDM1A Target Engagement Using Chemoprobe-based Immunoassays
Published on: June 13, 2019
Immunocapture-LC/MS-Based Target Engagement Measurement in Tumor Plasma Membrane
Abstract:
For targeted therapies, immunocapture-liquid chromatography mass spectrometry (IC-LC/MS) technology has become an important tool for determination of both drug exposures, target antigen densities, and engagement in the systemic circulation and/or in total target tissue homogenates. Although the information collected from the circulation and tissue homogenates is useful in establishing the correlations of the exposure and target engagement with the pharmacodynamic response and efficacy of a therapy, the measurement at the cell plasma membrane within the target tissue is preferred, since it is the primary action site for antigen and the target drug. However, to the best of our knowledge, IC-LC/MS-based methodologies to conduct the assays at the plasma membrane from tissue sample has been quite limited. In this paper, we reported an IC-LC/MS-based assay platform for assessing the target engagement in tumor plasma membrane prepared from the tumor tissue samples. In addition, tumor samples with guanylyl cyclase C (GCC) expression after fully human IgG1 monoclonal antibody-based antibody-drug conjugate (ADC) treatment were used as a case study. The methodology can differentiate between the total and target-drug bound fraction of GCC with minimal potential equilibrium shift between in-cell surface protein and organelle protein in tumor samples to calculate in vivo target engagement. This approach to determine in vivo target engagement in tumor plasma membrane will provide better understanding of pharmacokinetic/pharmacodynamic relationship to achieve the desired antitumor efficacy.
Insights
A new assay platform using immunocapture-liquid chromatography mass spectrometry (IC-LC/MS) measures drug target engagement directly on tumor cell membranes. This method enhances understanding of drug efficacy for targeted therapies.
Area of Science:
- Biomedical Science
- Analytical Chemistry
- Pharmacology
Background:
- Immunocapture-liquid chromatography mass spectrometry (IC-LC/MS) is crucial for assessing drug exposure and target engagement in targeted therapies.
- Current methods often analyze systemic circulation or tissue homogenates, but direct measurement at the cell plasma membrane, the primary drug action site, is preferred.
- Existing IC-LC/MS methodologies for plasma membrane analysis in tissue samples are limited.
Purpose of the Study:
- To develop and validate an IC-LC/MS assay platform for quantifying target engagement specifically at the tumor plasma membrane.
- To assess the in vivo target engagement of an antibody-drug conjugate (ADC) targeting guanylyl cyclase C (GCC) in tumor samples.
- To improve the understanding of pharmacokinetic/pharmacodynamic (PK/PD) relationships for enhanced antitumor efficacy.
Main Methods:
- Development of an IC-LC/MS assay platform for analyzing tumor plasma membrane preparations.
- Utilizing fully human IgG1 monoclonal antibody-based ADC treatment in tumor samples expressing GCC.
- Differentiating between total and target-drug bound GCC fractions to calculate in vivo target engagement with minimal equilibrium shift.
Main Results:
- Successfully established an IC-LC/MS assay platform for tumor plasma membrane analysis.
- Demonstrated the ability to accurately measure in vivo target engagement of an ADC targeting GCC.
- The method minimizes potential equilibrium shifts between cell surface and organelle proteins.
Conclusions:
- The developed IC-LC/MS assay provides a robust method for assessing in vivo target engagement at the tumor plasma membrane.
- This approach offers a more precise understanding of PK/PD relationships for targeted therapies.
- The methodology has the potential to optimize therapeutic strategies for improved antitumor efficacy.
Related Concept Videos
Enlargement of the Plasma Membrane
Plasma Membrane in Bacteria and Archaea
Fusion of Secretory Vesicles with the Plasma Membrane
In 1993, Jim Rothman proposed that the antiparallel pairing of vesicular and transmembrane SNAREs, or...
Introduction to Membrane Proteins
Composition of Blood Plasma
What are Membranes?

